Detection of KRAS Mutations Using Extracellular Vesicle DNA in Colorectal Cancer Patients
Cancer Science · 2025
DOI: 10.1111/cas.70059 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer Science, 2025. Verfasst von Sho Kuriyama und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Nippon Medical School, Tokyo, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Extracellular Vesicles, Mutation. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Department of Gastroenterological Surgery, Nippon Medical School.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Liquid biopsy using circulating tumor DNA (ctDNA) is useful for precision medicine and molecular‐guided oncology; however, its sensitivity is insufficient. We focused on DNA in extracellular vesicles (evDNA) as a new target for liquid biopsy and investigated its sensitivity. This observational study included 334 Stage I–IV colorectal cancer patients. evDNAs and ctDNAs were extracted from plasma collected before surgery. KRAS mutation status was analyzed using droplet digital PCR. One hundred and forty‐eight patients had KRAS mutations in tumor tissues, and 186 patients had no KRAS mutations. In Stage II (Stage II 37.8% vs. 13.3%, p = 0.015) or III (Stage III 43.1% vs. 13.6%, p = 0.001) patients, sensitivities to detect KRAS mutations using evDNA were higher than those using ctDNA. Surprisingly, evDNA identified KRAS mutations in 13.8% of patients who lacked them in tumor tissue samples. Among Stage III patients, those with higher concentrations of evDNA had significantly poorer relapse‐free survival compared with those who had lower concentrations of evDNA ( p = 0.043). The use of evDNA improved the identification rate of KRAS mutations. By using evDNA, KRAS mutations were identified in more than 10% of patients without KRAS mutations in their tumor tissues. The concentration of evDNA can be a prognostic factor for Stage III colorectal cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterological Surgery, Nippon Medical School, Tokyo, Japan.
- Department of Clinical Oncology, Kawasaki Medical University, Kurashiki, Japan.
ORCID-Profile: Takeshi Yamada, Toshimitsu Miyasaka, Ryo Ohta, Kohki Takeda, Koji Ueda, Seiichi Shinji
Förderung
- Japan Society for the Promotion of Science
- Department of Gastroenterological Surgery, Nippon Medical School
Zitieren
APA
Kuriyama, S., Yamada, T., Miyasaka, T., Uehara, K., Ohta, R., Matsuda, A., Takahashi, G., Iwai, T., Takeda, K., Ueda, K., Kanaka, S., Yokoyama, Y., Shinji, S., Sonoda, H., Nagasaka, T., & Yoshida, H. (2025). Detection of KRAS Mutations Using Extracellular Vesicle DNA in Colorectal Cancer Patients. Cancer Science. https://doi.org/10.1111/cas.70059
Vancouver
Kuriyama S, Yamada T, Miyasaka T, Uehara K, Ohta R, Matsuda A, et al. Detection of KRAS Mutations Using Extracellular Vesicle DNA in Colorectal Cancer Patients. Cancer Science. 2025. doi:10.1111/cas.70059
BibTeX
@article{Kuriyama2025,
author = {Kuriyama, Sho and Yamada, Takeshi and Miyasaka, Toshimitsu and Uehara, Kay and Ohta, Ryo and Matsuda, Akihisa and Takahashi, Goro and Iwai, Takuma and Takeda, Kohki and Ueda, Koji and Kanaka, Shintaro and Yokoyama, Yasuyuki and Shinji, Seiichi and Sonoda, Hiromichi and Nagasaka, Takeshi and Yoshida, Hiroshi},
title = {Detection of KRAS Mutations Using Extracellular Vesicle DNA in Colorectal Cancer Patients},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.70059}
}
EUVIMED